CALGB-90202

A Randomized Double-Blind, Placebo-Controlled Phase III Study of Early Versus Standard Zoledronic Acid to Prevent Skeletal Related Events in Men With Prostate Cancer Metastatic to Bone

ClinicalTrial.gov Identifier: NCT00079001

Study Background

Trial Description

RATIONALE: Zoledronate may prevent or decrease skeletal (bone)-related events (such as pain or fractures) caused by bone metastases and androgen deprivation therapy. It is not yet known whether treatment with zoledronate is effective in preventing bone-related events in patients who have prostate cancer and bone metastases. PURPOSE: This randomized phase III trial is studying how well zoledronate works in preventing bone-related events in patients who are receiving androgen deprivation therapy for prostate cancer and bone metastases.

Arms:

Zoledronic acid + androgen deprivation therapy: (Experimental): 4mg by IV over 15 minutes every 4 weeks in the absence of disease progression or the first skeletal-related event. Participants who progress on blinded treatment before having a skeletal event may continue on open label Zoledronic acid (4 mg by IV over 15 minutes every 3 weeks).

Placebo + androgen deprivation therapy: (Active Comparator): Placebo by IV over 15 minutes for 4 weeks in the absence of disease progression or the first skeletal-related event. Participants who progress on blinded treatment before having a skeletal event may continue on open label Zoledronic acid.

Objectives:

- Zoledronic acid decreases the risk of skeletal related events in men with prostate cancer metastatic to bone and disease progression after primary hormonal therapy.
- This study is designed to evaluate whether earlier treatment with zoledronic acid will further decrease the risk of skeletal related events. This is a randomized, double-blind, placebo-controlled, multicenter study followed by an open-label study. Patients are stratified according to ECOG performance status (0-1 vs 2), prior skeletal-related event (no vs yes), and serum alkaline phosphatase (< upper limit of normal [ULN] vs ≥ ULN).

- The primary objective of the study is to determine whether treatment with zoledronic acid at the time of initiation of androgen deprivation therapy for metastatic prostate cancer will delay the time to first skeletal related event. The secondary objective of the study is to compare the effect of treatment with zoledronic acid to placebo on overall survival (OS), progression-free survival (PFS) and toxicity in men receiving androgen deprivation therapy for metastatic prostate cancer.
- Patients are randomized to 1 of 2 treatment arms. Treatment continues in the absence of disease progression or a skeletal-related event. All patients receive concurrent androgen deprivation therapy with a GnRH agonist. Patients also receive oral calcium and (vitamin D) supplements daily. Patients progressing to androgen-independent prostate cancer proceed to the open-label therapy with zoledronic acid IV. Treatment continues for 3 weeks in the absence of disease progression or the first skeletal-related event.
- Patients are followed periodically for approximately 10 years after entry on the study.

Study Milestones:

Start date: January 2004

Primary Completion Date: July 2012

Publication Information:

Analysis Type: Primary

Pubmed ID: 24590644

Citation: J Clin Oncol. 2014 Apr 10;32(11):1143-50. doi: 10.1200/JCO.2013.51.6500. Epub 2014 Mar 3.

Associated Datasets: NCT00079001-D1-Dataset.csv (baseline), NCT00079001-D2-Dataset.csv (analysis), NCT00079001-D3-Dataset.csv (ae)

Dataset Information:

Dataset Name: NCT00079001-D1-Dataset.csv (baseline)

Description: NCT00079001-D1-Dataset.csv (baseline) is one of 3 datasets associated with PubMed ID 24590644. This dataset contains information that will allow you to reproduce the baseline characteristics table.

NCT00079001-D1-Dataset.csv (baseline) Data Dictionary:

LABEL	NAME	elements	comments
PATIENT_ID	PATID		De-Identified patient reference
Treatment Assignment	TREAT_ASSIGNED	1 = Zoledronic acid 2 = Placebo	
Stratification Factor: ECOG performance	stratps	0 = Normal 1 = Ambulatory 2 = <50% Time in bed	
Stratification Factor: Prior Skeletal Related Event	stratpsre	0 = No 1 = Yes	
Stratification Factor: Serum Alkaline Phosphatase	stratap	1 = < ULN 2 = >=ULN	
Combined Gleason Score	GLEAST	-2 = Unknown Otherwise literal score	
Gleason Score based on specimen type	GLEASTYPE	-2 = Unknown 1 = Biopsy 2 = Surgical specimen, Missing=unreported	
Prior prostatectomy	PRPROSTEC	-2 = Unknown 1 = No 2 = Yes Missing=unreported	
Prior prostate radiation therapy	PRPROSTXRT	-2 = Unknown 1 = No 2 = Yes Missing=unreported	

Prior prostate radiation therapy type	PRPROSTXRTTYPE	-2 = Unknown 1 = External beam 2 = Brachytherapy (implant) 3 = Both Missing=unreported	
Prior neoadjuvant hormone therapy	PRNAHT	-2 = Unknown 1 = No 2 = Yes Missing=unreported	
Enrolling in CALGB 9594	PATIENT9594	-2 = Unknown 1 = No 2 = Yes Missing=unreported	
Type of ADT at enrollment	HTTYPE	-2 = Unknown 1 = Orchiectomy alone 2 = Orchiectomy + antiandrogen 3 = LHRH agonist alone 4 = LHRH agonist + antiandrogen Missing=unreported	
LUNG Metastatic/Recurrent Site	LUNG	1 = No 2 = Yes Missing=Not reported	
LIVER Metastatic/Recurrent Site	LIVER	1 = No 2 = Yes Missing =Not reported	
PLEURA Metastatic/Recurrent Site	PLEURA	1 = No 2 = Yes Missing =Not reported	
CNSNOBRAIN Metastatic/Recurrent Site	CNSNOBRAIN	1 = No 2 = Yes Missing =Not reported	
BONE	BONE	1 = No	

Metastatic/Recurrent Site		2 = Yes Missing =Not reported	
SOFTTISSUE Metastatic/Recurrent Site	SOFTTISSUE	1 = No 2 = Yes Missing =Not reported	
Other Metastatic/Recurrent Site	SITEOTH	1 = No 2 = Yes Missing =Not reported	
Hemoglobin mg/dL	HGB	Continuous	Missing values were cases where value was not reported.
Calcium Serum mg/dL	CASERUM	Continuous	Missing values were cases where value was not reported.
Lactate dehydrogenase U/L	LDH	Continuous	Missing values were cases where value was not reported or unknown.
Alkaline phosphatase U/L	ALKPHOS	Continuous	Missing values were cases where value was not reported or unknown.
Baseline PSA value ng/mL	PSA1	Continuous	Missing values were cases where value was not reported or unknown.
Baseline Creatinine mg/dL	CREATBASE	Continuous	Missing values were cases where value was not reported or unknown.
Race	racecat	1 = White 99 = other/unknown Missing=unreported	

Age when patient started study	age	Continuous	